Copland Road Capital Corporation

Operating as a principal investment firm, Copland Road Capital Corporation, previously known as Nabis Holdings Inc., dedicates its capital deployment to the cannabis industry. The company primarily targets investment opportunities within the United States. Its strategy involves acquiring controlling (majority) stakes in the businesses it finances and often prefers that selling entities accept a significant part of their payment in the form of company equity. Established in 2002, Copland Road Capital Corporation is headquartered in Vancouver, Canada, and also maintains an office in Toronto.

Copland Road Capital Corporation trades as CRCC.CN on CNQ. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in CAD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $0 of revenue and -$585,254 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Copland Road Capital Corporation can be compared against peers such as Captor Capital Corp., Doseology Sciences Inc., Ovation Science Inc., Planet Based Foods Global Inc., Premier Health of America Inc., Pharmadrug Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $1.44M, beta of 0.24, and return on equity of -75.8%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

CRCC.CN currently shows total debt of $0 and beta of 0.24. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.copland-road.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.